Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) benefit from innovative treatments for obesity and diabetes. Start Your ...

The health benefits of time-restricted eating go beyond weight loss and may be most prominent in patients already with ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Summit Partners has hired Ricardo Gonzalez as a partner on the firm’s growth products and services team.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

With the close of 2024 and the launch of a new year, we can take a moment to look back at what was another eventful, ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.